Perrigo Animal Health and Piedmont Animal Health jointly announce that an agreement has been signed between the two companies to develop and commercialize a number of FDA-regulated medications for the companion animal market. Piedmont will be primarily responsible for developing and gaining regulatory approval, and Perrigo will commercialize the products and make them available through its world-class supply chain network.
The agreement will propel several new animal drug applications (NADAs) and generic drugs already in development at Piedmont. This partnership is the first between the two companies.
“Perrigo delivers high-quality pet health products to consumers through its portfolio of leading brands such as PetArmor, Sentry and Petrodex. We are committed to accelerating category sales by increasing retailer and consumer access to new and innovative products,” said Neal Wilmore, vice president and general manager of Perrigo Animal Health. “The strategic partnership with Piedmont Animal Health is another example of our efforts to invest in and deliver new products to consumers searching for vet quality solutions with the convenience and affordability of a retail purchase.”
“Piedmont has been one of the most successful pharmaceutical companies in the industry in developing and gaining regulatory approval for animal health products,” said Roland Johnson, CEO of Piedmont. “We recognize that various products fit different channels, so we have recently expanded our third- party work accordingly. We are pleased that this partnership with Perrigo is the first to result from this expansion. Furthermore, Perrigo has a strategic vision that aligns with our own as well as an experienced commercial team to exploit novel product opportunities.”